2012 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
Date Title
Dec 10, 2012Printer Friendly VersionMillennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Hodgkin Lymphoma at ASH Annual Meeting
Dec 10, 2012Printer Friendly VersionData Reported From Phase 1 Study of Once a Week MLN9708 Oral Proteasome Inhibitor in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis
Dec 09, 2012Printer Friendly VersionPresentations Highlight Data on VELCADE® (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma
Dec 09, 2012Printer Friendly VersionMillennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas
Dec 09, 2012Printer Friendly VersionOnce a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1/2 study
Nov 05, 2012Printer Friendly VersionVELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Millennium Pipeline Agents to be Featured at American Society of Hematology Annual Meeting
Nov 05, 2012Printer Friendly VersionMillennium is #1 in Boston Globe Ranking of Top Largest Employer
Nov 01, 2012Printer Friendly VersionMillennium and Seattle Genetics Initiate Global Phase 3 Clinical Trial of ADCETRIS® in Previously Untreated Advanced Hodgkin Lymphoma
Oct 31, 2012Printer Friendly VersionMillennium and Takeda Announce European Conditional Marketing Authorization for ADCETRIS® (Brentuximab Vedotin)
Oct 19, 2012Printer Friendly VersionMillennium Initiates Global TOURMALINE-AL1 Pivotal Phase 3 Trial of MLN9708 In Patients with Relapsed or Refractory Primary (AL) Amyloidosis
Oct 01, 2012Printer Friendly VersionMillennium and Seattle Genetics Highlight Data from ADCETRIS® (Brentuximab Vedotin) Trial in Patients with Newly Diagnosed Systemic Anaplastic Large Cell
Sep 25, 2012Printer Friendly VersionSeattle Genetics and Millenium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS® for Post-Transplant Patients with Hodgkin Lymphoma
Sep 21, 2012Printer Friendly VersionMillennium Ranked In Top 10 Biotech / Biopharmaceutical Companies For 5th Consecutive Year
Jul 20, 2012Printer Friendly VersionMillennium and Takeda Announce Positive CHMP Opinion for Conditional Approval of ADCETRIS® (brentuximab vedotin) in Europe
Jun 28, 2012Printer Friendly VersionMillennium Initiates TOURMALINE-MM1 Pivotal Phase 3 Trial of MLN9708 in Patients With Relapsed and/or Refractory Multiple Myeloma
Jun 14, 2012Printer Friendly VersionMillennium Highlights Updated Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Patients with Relapsed or Refractory Hodgkin Lymphoma
Jun 04, 2012Printer Friendly VersionClinical Data Presented on Orteronel (TAK-700) Without Steroids in Non-Metastatic Prostate Cancer
Jun 03, 2012Printer Friendly VersionASCO Presentations Highlight Preliminary Results of Studies with MLN9708, First Oral Proteasome Inhibitor in Clinical Trials in Multiple Myeloma
May 23, 2012Printer Friendly VersionMillennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting
May 07, 2012Printer Friendly VersionMillennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma
Apr 12, 2012Printer Friendly VersionSeattle Genetics and Millennium to Collaborate with Ventana on Companion Diagnostic for ADCETRIS™ in CD30-Positive Malignancies
Apr 06, 2012Printer Friendly VersionPresage Biosciences and Millennium Enter Into Cancer Research Agreement
Mar 05, 2012Printer Friendly VersionMillennium Initiates Pivotal Phase 3 Trial of MLN8237 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Jan 26, 2012Printer Friendly VersionSeattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ in Front-line Mature T-Cell Lymphomas
Jan 23, 2012Printer Friendly VersionFDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
Jan 19, 2012Printer Friendly VersionFortune Magazine Names Millennium Among 100 Best Companies To Work For